Lead Product(s): Faricimab
Therapeutic Area: Ophthalmology
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2020
The data suggests that faricimab, the experimental drug could be given once every 12 or 16 weeks, as opposed to the 4 weeks required for their long-running AMD blockbuster Lucentis.